Skip to content
Asked what this pandemic taught us that will help us prepare for the next one, a panel of experts mentioned the need to improve […]
COVID lessons on manufacturing, distribution, regulation Read More »
One of the key lessons of the COVID-19 pandemic has been the need to strengthen government support for biotechnology, with direct funding but also
Top officials share a key COVID lesson: Governments must support biotech Read More »
The United States is the world leader in biotechnology, but the country wasn’t always on top, and there’s obviously no guarantee it will stay
BIO expert: China pushes WTO IP waiver to gain tech access Read More »
Certain serious psychiatric or gastrointestinal conditions require neuroleptic drugs, which are designed to block dopamine receptors in the brain and central nervous system, but
Awareness of tardive dyskinesia is the best defense Read More »
Nkarta today announced positive preliminary data in two Phase 1 clinical trials of its natural killer cell therapies to treat patients with advanced blood
Nkarta announces positive preliminary results with natural killer cell cancer therapies Read More »
In an article in the International Business Times, BIO President and CEO Dr. Michelle McMurry-Heath outlines the problems with a proposed international IP waiver
BIO’s View: How to really close the global vaccine gap Read More »
Medicare will cover breakthrough Alzheimer’s drug Aduhelm only for participants in clinical trials, says the final national coverage determination—an “enormous setback for Alzheimer’s patients
CMS restricts coverage of Alzheimer’s drug to patients in clinical trials Read More »
The prognosis for the world on World Health Day is concerning. We are still battling a pandemic, and rising numbers in diseases like cancer,
World Health Day focuses on how the planet’s health impacts ours Read More »
Reauthorization of FDA user fee agreements will strengthen dialogue and advance innovation, Biotechnology Innovation Organization (BIO) Chief Scientific Officer Dr. Cartier Esham told the
BIO’s CSO tells Senate PDUFA is ‘critical to advancing innovation’ Read More »
Legislation to modernize the clinical drug development paradigm should be patient-centric, effective and inclusive, Biotechnology Innovation Organization (BIO) Chief Scientific Officer Dr. Cartier Esham
BIO’s CSO testifies at congressional hearing on PDUFA riders Read More »
